The FDA has granted the ProSense Cryoablation System marketing authorization for small, low-risk breast cancers in women at least 70 years of age who receive adjuvant endocrine therapy. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback